他泽司他能治好上皮样未分化肉瘤吗？

Epithelioid undifferentiated sarcoma generally cannot be cured, but it can improve the objective response rate and prolong the patient's survival. It is recommended that patients maintain a good attitude and take active treatment under the guidance of a doctor.

Treatment of tazerestat epithelioid sarcoma

A study reports the clinical activity and safety of tazerestat in patients with epithelioid sarcoma, a rare and aggressive subtype of soft tissue sarcoma.

Methods: In an open phase 2 basket study, patients from 32 hospitals and clinics in Australia, Canada, France, and the United States were divided into 7 groups, each with a different INI1-negative solid tumor or synovial sarcoma. Patients eligible for the epithelioid sarcoma cohort (cohort 5) were 16 years of age or older and had histologically confirmed locally advanced or metastatic epithelioid sarcoma. or biallelic SMARCB1 by immunohistochemical analysis. Patients received 800 mg of tazerestat orally twice daily in consecutive 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent.

The primary endpoint was investigator-assessed objective response rate according to Response Evaluation Criteria in Solid Tumors (version 1.1). Secondary endpoints were duration of response, disease control rate at 32 weeks, progression-free survival, overall survival, and pharmacokinetic and pharmacodynamic analyzes (primary results reported elsewhere). Reaction time was also assessed as an exploratory endpoint. Activity and safety were evaluated in a modified intention-to-treat population (i.e., patients who received one or more doses of tazerestat).

Results: Sixty-two patients with epithelioid sarcoma were enrolled in the study and deemed eligible for inclusion in the cohort. All 62 patients were included in the modified intention-to-treat analysis. Nine of 62 patients had an objective response at data cutoff. At a median follow-up of 138 months, the median duration of response had not been reached, and 16 patients had disease control at 32 weeks. The median progression-free survival was 55 months, the median time to response was 39 months, and the median overall survival was 190 months. Grade 3 or worse treatment-related adverse events included anemia and weight loss.

CONCLUSIONS: Tazerestat is well tolerated and clinically active in a cohort of patients with advanced epithelioid sarcoma characterized by INI1/SMARCB1 loss. Tazerestat has the potential to improve outcomes for patients with advanced epithelioid sarcoma.

Medication

1. After treatment with tazerestat, the risk of secondary malignant tumors increases. Patients should be monitored over the long term for the development of secondary malignancies.

2. Tazerestat has embryo-fetal toxicity and will cause harm to the fetus when administered to pregnant women. Pregnant women should be informed of the potential risks to the fetus and should use effective contraception during treatment and for 6 months after the last dose.

Recommended related articles: